Experts say the approach could also save millions of pounds by cutting projects or clinical trials that would otherwise fail.

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

In attempt to keep R&D costs low, the vivarium business model has emerged as a crucial solution for drug developers.

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...

Cell membrane proteins hide secret gateways that can be used to modify cell behavior. This has been demonstrated in a study ...

Artificial intelligence has already made its mark in commercial industries, and there's a good argument to be made that AI is most impactful in the drug discovery marketplace: Drug discovery companies ...

The United States has led the world in pharmaceutical innovation for decades by developing drugs that combat cancer, heart ...

Bio-conjugation techniques utilizing proteins, such as attaching fluorescent markers to identify cancer cells, are actively ...

The future of American drug innovation is threatened by U.S. regulations that permit knockoff versions of new drugs to be ...

This comprehensive review analyzes cutting-edge tools and technologies in modern pharmaceutical research, focusing on ...

The ongoing conflicts between Ukraine and Russia, as well as Israel and Palestine, have sent ripples across various ...

Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...